Part 3: Newer therapies for ANCA-associated vasculitis.
Jayne
D
D
Renal Unit, Addenbrooke's Hospital, Cambridge, UK. dj106@cam.ac.uk
D000818:Animals; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D004195:Disease Models, Animal; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008212:Lymphocyte Depletion / Q000379:methods*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014657:Vasculitis / Q000276:immunology / Q000628:therapy*
D019268:Antibodies, Antineutrophil Cytoplasmic; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha